DLBCL
MCID: DFF005
MIFTS: 55

Diffuse Large B-Cell Lymphoma (DLBCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 12 20 58 15 37 17 70 32
Dlbcl 20 58
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 70
Large B-Cell Diffuse Lymphoma 73

Characteristics:

Orphanet epidemiological data:

58
diffuse large b-cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (France); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050745
ICD10 32 C83.3
MESH via Orphanet 45 D016403
ICD10 via Orphanet 33 C83.3
UMLS via Orphanet 71 C0079744
Orphanet 58 ORPHA544
UMLS 70 C0079744 C2699777

Summaries for Diffuse Large B-Cell Lymphoma

GARD : 20 Diffuse large B- cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer. Lymphomas occur when cells of the immune system, known as B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss. Treatment may differ depending on the location of the tumor and the subtype of lymphoma. For those who have advanced DCBCL and have not been treated previously, a combination of chemotherapy and the monoclonal antibody rituximab (Rituxan) ( R-CHOP ) may be tried. . In addition, as of October 2017, axicabtagene ciloleucel (brand name: Yescarta), a type of gene therapy, has been approved by the United States FDA to treat DCBCL that is not responding to at least two treatment attempts or has returned after being treated before. A stem cell transplant may also be an option if DLBCL returns or relapses.

MalaCards based summary : Diffuse Large B-Cell Lymphoma, also known as dlbcl, is related to b-cell lymphoma and burkitt lymphoma. An important gene associated with Diffuse Large B-Cell Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Epirubicin and Anti-Retroviral Agents have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, breast and t cells.

Disease Ontology : 12 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia : 73 Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible... more...

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 870)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphoma 33.4 MIR21 MIR17HG MIR17 MIR155 HOTAIR
2 burkitt lymphoma 31.7 MIR21 MIR17HG MIR155 MIR145 MIR143 MIR127
3 leukemia, acute lymphoblastic 31.3 MIR221 MIR210 MIR21 MIR17 MIR155
4 leukemia, acute myeloid 31.3 MIR221 MIR210 MIR21 MIR17 MIR155 MIR127
5 leukemia, chronic lymphocytic 31.3 PEG10 MIR221 MIR21 MIR17HG MIR17 MIR155
6 myeloma, multiple 31.2 MIR21 MIR17 MIR145 HOTAIR
7 disease by infectious agent 31.2 MIR221 MIR21 MIR17 MIR155
8 dermatomyositis 31.1 MIR221 MIR210 MIR21 MIR155
9 thyroid cancer, nonmedullary, 1 31.0 MIR221 HULC HOTAIR
10 nasopharyngeal carcinoma 30.9 MIR21 MIR17 MIR143 HULC HOTAIR
11 glioblastoma 30.7 MIR221 MIR210 MIR21 MIR17HG MIR155 HOTAIR
12 rectum cancer 30.6 MIR21 MIR17 MIR145 MIR143
13 polymyositis 30.6 MIR221 MIR210 MIR21 MIR155 MIR127
14 leukemia, chronic myeloid 30.6 MIR17 MIR10A HULC HOTAIR
15 central nervous system disease 30.5 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
16 glioma 30.5 MIR221 MIR210 MIR21 MIR17 HULC HOTAIR
17 renal cell carcinoma, nonpapillary 30.4 PANDAR MIR221 MIR210 MIR21 MIR17 MIR155
18 nervous system disease 30.4 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
19 gastric cancer 30.3 PANDAR MIR221 MIR21 MIR17 MIR155 MIR145
20 gallbladder disease 30.3 MIR17 MIR145 MIR143
21 lipoprotein quantitative trait locus 30.2 MIR221 MIR21 MIR17 MIR155 MIR145 MIR143
22 lymphatic system cancer 30.2 MIR221 MIR21 MIR17 MIR155 MIR145 MIR143
23 intestinal disease 30.2 MIR221 MIR21 MIR17 MIR155 MIR145 MIR143
24 connective tissue disease 30.2 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
25 bladder cancer 30.2 PANDAR MIR221 MIR21 MIR17 MIR145 MIR143
26 esophageal cancer 30.2 PEG10 MIR21 MIR145 MIR143 HULC HOTAIR
27 gastrointestinal system disease 30.1 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
28 arteries, anomalies of 30.1 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
29 heart disease 30.0 MIR210 MIR21 MIR17 MIR155 MIR145 MIR143
30 prostate cancer 29.9 MIR221 MIR210 MIR21 MIR17 MIR145 MIR143
31 lymphoma 11.9
32 relapsed/refractory diffuse large b-cell lymphoma 11.8
33 gray zone lymphoma 11.7
34 primary cutaneous diffuse large b-cell lymphoma, leg type 11.7
35 lymphoma, non-hodgkin, familial 11.6
36 primary central nervous system lymphoma 11.6
37 plasmablastic lymphoma 11.6
38 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 11.6
39 diffuse large b-cell lymphoma of the central nervous system 11.6
40 follicular lymphoma 11.5
41 diffuse large b-cell lymphoma with chronic inflammation 11.5
42 reticulosarcoma 11.5
43 t-cell/histiocyte rich large b cell lymphoma 11.4
44 mediastinal gray zone lymphoma 11.4
45 primary mediastinal b-cell lymphoma 11.4
46 richter's syndrome 11.4
47 lymphoma, hodgkin, classic 11.4
48 neutropenia 11.1
49 thrombocytopenia 11.0
50 mantle cell lymphoma 10.9

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 253)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2 Anti-Retroviral Agents Phase 4
3
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
4
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
5
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
6
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Mesna Approved, Investigational Phase 3 3375-50-6 598
9
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
10
Vinblastine Approved Phase 3 865-21-4 241903 13342
11
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
12
Pixantrone Approved, Investigational Phase 3 144510-96-3
13
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
14
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
15
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
16
rituximab Approved Phase 3 174722-31-7 10201696
17
Lenograstim Approved, Investigational Phase 3 135968-09-1
18
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
19
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
20
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
21
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
22
Etoposide Approved Phase 3 33419-42-0 36462
23
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
24
Gemcitabine Approved Phase 3 95058-81-4 60750
25
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
26
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
27
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
28
Carmustine Approved, Investigational Phase 3 154-93-8 2578
29
Melphalan Approved Phase 3 148-82-3 4053 460612
30
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
31
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
32
Bevacizumab Approved, Investigational Phase 3 216974-75-3
33
Phenylalanine Approved, Investigational, Nutraceutical Phase 3 63-91-2 6140
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
35
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
36
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
37
Buformin Investigational, Withdrawn Phase 2, Phase 3 692-13-7
38
Molgramostim Investigational Phase 3 99283-10-0
39 Reverse Transcriptase Inhibitors Phase 2, Phase 3
40 Anti-HIV Agents Phase 2, Phase 3
41
Isophosphamide mustard Phase 3 100427
42 Neuroprotective Agents Phase 3
43 Protective Agents Phase 3
44 Fluorodeoxyglucose F18 Phase 3
45 Hematinics Phase 3
46 Epoetin alfa Phase 3 113427-24-0
47 Podophyllotoxin Phase 3 518-28-5
48 Keratolytic Agents Phase 3
49 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
50 Hypoglycemic Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 639)
# Name Status NCT ID Phase Drugs
1 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
2 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
3 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
4 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
6 A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT,in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL Unknown status NCT03213977 Phase 3 R-DA-EPOCH;R-DA-EPOCH + auto-HSCT;R-CEOP90;R-CEOP90 + auto-HSCT
7 A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
8 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
9 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
10 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
11 Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma Unknown status NCT02767674 Phase 3 Rituximab;Gemcitabine;Oxaliplatin;Cyclophosphamide;Epirubicin Injectable Product;Vindesine;Prednisone
12 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
13 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
14 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
15 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
16 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
17 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
18 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
19 Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma Unknown status NCT03018626 Phase 3 Rituximab;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Doxorubicin;Cyclophosphamide;Vindesine;Bleomycin
20 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Unknown status NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
21 Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03229616 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
22 An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients Unknown status NCT03318835 Phase 3 Thalidomide combined with R-CHOP;R-CHOP
23 A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
24 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
25 Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas Completed NCT00355199 Phase 3 Rituximab-HDS;Rituximab-CHOP
26 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Completed NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
27 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
28 An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
29 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
30 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
31 A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma Completed NCT03372837 Phase 3 Rituximab
32 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
33 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
34 A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
35 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
36 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
37 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
38 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Completed NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
39 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed NCT01855750 Phase 3 Ibrutinib;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone (or equivalent)
40 Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
41 Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. Completed NCT00144755 Phase 3 Darbepoetin alfa
42 Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
43 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
44 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
45 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
46 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
47 Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+ Completed NCT01285765 Phase 3 RCHOP21
48 Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line Completed NCT01122472 Phase 3 Lenalidomide;Placebo
49 Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL Completed NCT02787239 Phase 3 HLX01;Rituximab;CHOP
50 Multicenter, Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH-21, R-mNHL-BFM-90 and (Auto-SCT)in Patients With DLBCL Recruiting NCT02842931 Phase 3 R-DA-EPOCH-21;R-DA-EPOCH-21 + auto-SCT;R-mNHL-BFM-90;R-mNHL-BFM-90 + auto-SCT

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma:

40
Bone Marrow, Breast, T Cells, B Cells, Thyroid, Myeloid, Kidney

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 13972)
# Title Authors PMID Year
1
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. 47 61
19287466 2009
2
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 61 47
18537969 2008
3
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. 47 61
18318758 2008
4
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. 47 61
17487835 2007
5
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. 61 47
16041695 2005
6
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 47 61
15738415 2005
7
Downregulation of microRNAs-143 and -145 in B-cell malignancies. 47
17892514 2007
8
MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. 47
16675453 2006
9
A 10-year cohort study of 175 primary gastrointestinal lymphoma cases in Thailand: clinical features and outcomes in the immunochemotherapy era. 61
33618613 2021
10
Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway. 61
33649847 2021
11
Seminal vesicles tumor: Rare localization of lymphoma. A case report. 61
33489767 2021
12
Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis. 61
33128820 2021
13
Diffuse large B cell lymphoma presenting with renal failure and bone lesions in a 46-year-old woman: a case report and review of literature. 61
32989684 2021
14
Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis. 61
33629825 2021
15
Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. 61
32945547 2021
16
Non-Hodgkin Lymphoma Mimicking Endodontic Lesion: A Case Report with 3-dimensional Analysis, Segmentation, and Printing. 61
33493549 2021
17
Primary Central Nervous System Lymphoma Mimicking Longitudinally Extensive Transverse Myelitis. 61
33791064 2021
18
CAR-T cell therapy: practical guide to routine laboratory monitoring. 61
33685719 2021
19
The diagnosis of a giant cardiac malignant lymphoma in the right ventricle: a case report. 61
33529498 2021
20
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. 61
33448873 2021
21
Double percutaneous transesophageal gastrotubing precluded high risk surgery for intestinal malignant lymphoma. 61
33747497 2021
22
A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel. 61
33385585 2021
23
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy. 61
33512026 2021
24
Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. 61
33608849 2021
25
Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders. 61
33793378 2021
26
Varicella Zoster Viral Retinitis following Chimeric Antigenic Response T-cell Therapy for B-cell Lymphoma. 61
33797314 2021
27
Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. 61
33787861 2021
28
Mutational landscape of gray zone lymphoma. 61
32961552 2021
29
Secondary cutaneous involvement by direct extension in high-grade B-cell lymphomas. 61
32639608 2021
30
Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma. 61
33416909 2021
31
Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma. 61
33664809 2021
32
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. 61
33529419 2021
33
Case report of primary dural lymphoma mimicking a cerebellar meningioma and brief review of literature. 61
31301042 2021
34
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial. 61
33751401 2021
35
Epstein-Barr Virus-associated Diffuse Large B-cell Lymphoma Identified in a Breast Implant Capsule: A New Breast Implant-Associated Lymphoma? 61
33720919 2021
36
New developments in non-Hodgkin lymphoid malignancies. 61
33685720 2021
37
Genomic characterisation of diffuse large B-cell lymphoma. 61
33642095 2021
38
PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. 61
33579170 2021
39
Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80-results from a single-center survey. 61
33634349 2021
40
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma. 61
33325309 2021
41
Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice. 61
33024996 2021
42
A case of primary cutaneous B-cell lymphoma with immature features in an old man. Diffuse large B-cell lymphoma with immature features or B-cell lymphoblastic lymphoma? 61
32623764 2021
43
Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609. 61
33792675 2021
44
Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases. 61
33610538 2021
45
Impact of Diffuse Large B-Cell Lymphoma on Mammography and Bone Density Testing in Women. 61
33710443 2021
46
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. 61
33274677 2021
47
Ineffectiveness of High-Dose Methotrexate for Prevention of CNS Relapse in Diffuse Large B Cell Lymphoma. 61
33811794 2021
48
Clinicopathological and genetic characteristics of diffuse large B-cell lymphoma of the oropharyngeal and maxillofacial region. 61
32731312 2021
49
Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma. 61
33811277 2021
50
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. 61
33528286 2021

Variations for Diffuse Large B-Cell Lymphoma

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

7 (show top 50) (show all 118)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain ECI1 Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19B Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FCSK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain ST3GAL2 Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain KMT2B Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 MIR221 MIR210 MIR17HG MIR17
2 11.72 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
3 11.18 MIR17HG MIR17 MIR127 MIR10A
4 11.03 MIR221 MIR210 MIR145

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MIR221 MIR210 MIR21 MIR17 MIR155 MIR143

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.81 MIR221 MIR155 MIR145
2 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.69 MIR221 MIR21 MIR17
3 positive regulation of blood vessel endothelial cell migration GO:0043536 9.67 MIR221 MIR210 MIR143
4 negative regulation of angiogenesis GO:0016525 9.67 MIR21 MIR145 MIR143 MIR10A
5 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.65 MIR21 MIR17
6 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.64 MIR21 MIR10A
7 positive regulation of cardiac muscle hypertrophy GO:0010613 9.64 MIR21 MIR155
8 negative regulation of necroptotic process GO:0060546 9.63 MIR221 MIR155
9 negative regulation of innate immune response GO:0045824 9.62 MIR21 MIR155
10 positive regulation of macrophage activation GO:0043032 9.62 MIR155 MIR145
11 negative regulation of cardiac muscle hypertrophy GO:0010614 9.61 MIR21 MIR145
12 regulation of smooth muscle contraction GO:0006940 9.61 MIR145 MIR143
13 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.6 MIR17 MIR155
14 negative regulation of cell adhesion molecule production GO:0060354 9.59 MIR221 MIR155
15 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.58 MIR17 MIR155
16 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR17 MIR155
17 negative regulation by host of viral genome replication GO:0044828 9.57 MIR221 MIR155
18 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.56 MIR221 MIR155
19 positive regulation of metalloendopeptidase activity GO:1904685 9.55 MIR21 MIR17
20 angiotensin-activated signaling pathway GO:0038166 9.54 MIR145 MIR143
21 negative regulation of regulatory T cell differentiation GO:0045590 9.52 MIR21 MIR155
22 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.5 MIR221 MIR21 MIR143
23 aorta smooth muscle tissue morphogenesis GO:0060414 9.48 MIR145 MIR143
24 negative regulation of interleukin-21 production GO:0032705 9.46 MIR221 MIR21
25 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.43 MIR17 MIR143
26 miRNA mediated inhibition of translation GO:0035278 9.43 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
27 regulation of phenotypic switching GO:1900239 9.4 MIR145 MIR143
28 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.33 MIR210 MIR21 MIR17
29 gene silencing by miRNA GO:0035195 9.32 MIR221 MIR210 MIR21 MIR17HG MIR17 MIR155
30 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR145 MIR143

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR221 MIR210 MIR21 MIR17HG MIR17 MIR155
2 mRNA 3'-UTR binding GO:0003730 9.26 MIR21 MIR17 MIR145 MIR143

Sources for Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....